Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actuate 1801 study of 9-ING-41 in refractory hematologic malignancies or solid tumors
NL-OMON55073Phase 2Completed
- Sponsor
- Actuate Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elraglusib in hematopoietic malignancies, Nonhematologic neoplasms, pancreatic cancer (PC) and 4 more (8 arms), sponsored by Actuate Therapeutics. Primary endpoints: Safety and tolerability, Dose-limiting toxicity and 7 more. Started Jun 2020; status: completed.
02
Drugs
elraglusib
03
Conditions
hematopoietic malignanciesNonhematologic neoplasmspancreatic cancer (PC)glioblastoma (GBM)Neuro-Oncological Malignancies
Beyond the preview
Go deeper on NL-OMON55073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55073.